Julien Moehlin
Strasbourg, 67000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.
Journal: Science translational medicine
Published: June 03, 2026
HDV sensing drives USP18-mediated refractoriness to IFN-α response, sparing IFN-β/λ in hepatocytes.
Journal: Antiviral research
Published: February 20, 2026
Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole.
Journal: Hepatology (Baltimore, Md.)
Published: August 13, 2025
Hepatitis B virus-infected hepatocytes promote the secretion of collagen VI to the extracellular matrix.
Journal: Scientific reports
Published: December 02, 2024
Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease.
Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease.
Journal: eGastroenterology
Published: October 30, 2024
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.
Journal: Journal of hepatology
Published: September 13, 2024
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair.
Journal: Frontiers in molecular neuroscience
Published: April 02, 2024
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development.
Journal: Nature communications
Published: September 04, 2023
Targeting the liver clock improves fibrosis by restoring TGF-β signaling.
Journal: Journal of hepatology
Published: May 05, 2023
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models.
Journal: The Journal of clinical investigation
Published: February 02, 2023
Last Updated: 09/26/2026